FDA - Food and Drug Administration

Targeted antibiotic gel helps 80% of pilot patients avoid foot amputation, Jerusalem trial finds

GentaGel’s biodegradable treatment releases antibiotics directly at infection sites for up to 60 days; the company is pursuing further trials and an FDA regulatory pathway.

Dr. Ariel Orbach (L), Co-Founder and CEO of GentaGel, Prof. Avi Domb (M), Inventor of GentaGel-LR Technology, and Eli Lerner (R), Co-founder and COO of GentaGel.
Menta "Steve" Wallace shows a bottle of daraxonrasib, Revolution Medicine?s pancreatic cancer drug, at his home in The Woodlands, Texas, U.S., May 29, 2026.

Revolution Medicines gets FDA approval for targeted pancreatic cancer drug

A close-up view of a large pile of green jalapeño peppers

What do we know about the multistate salmonella outbreak in the US? - explainer

The logo of US supplier Taylor Farms at the company's installations following the temporary closure announced by Taylor Farms, in Doctor Mora, Guanajuato state, Mexico, July 24, 2026.

Taylor Farms recalls salsa, guacamole over salmonella risk, weeks after cyclosporiasis concerns


Biden administration to allow new injection method for monkeypox vaccine

The United States declared monkeypox a public health emergency last week, in an effort to bolster the US response to contain the outbreak.

 US President Joe Biden delivers remarks on administration plans to fight inflation and lower costs during a speech in the Eisenhower Executive Office Building's South Court Auditorium at the White House in Washington, U.S., May 10, 2022.

Have breast implants? Israeli study warns they cause autoimmune, mental problems

Lack of FDA supervision, data on side effects hidden by companies resulted in severe autoimmune and mental complications * Permission in 1960s to allow the technology was a “historical medical error”

 Can silicone breast implants cause autoimmune complications? (Illustrative)

Israeli company SoniVie receives FDA approval for innovative hypertension treatment

SoniVie’s treatment is called TIVUS – an innovative Ultrasound system that treats Hypertension patients with Renal Artery Denervation. 

 SoniVie's TIVUS medical device.

US, Canada investigate Hepatitis A outbreak linked to strawberries

"Consumption of imported fresh organic strawberries is the likely source of the outbreak," American and Canadian health agencies said.

 Hepatitis A virus (HVA) causes acute inflammation of the liver and is the most common of all forms of viral hepatitis

US FDA clears Pfizer's COVID booster shot for young children

Children below the age of five are not yet eligible for a COVID-19 vaccine in the United States.

The Pfizer vaccine for children aged 5-11

State sues Teva over Copaxone drug royalties

Two doctors sued Teva for failing to acknowledge their contributions and demanded to be compensated with royalties stemming from the new version of copaxone.

Teva CEO Kåre Schultz at the Tel Aviv Stock Exchange, February 19, 2020

BioGenCell raises $16m. for chronic disease treatment

The company’s treatment has already prevented loss of limb in several patients during Phase I trials.

 Microglia (green) that were “matured” in the lab from stem cells of ALS patients; the cells’ nuclei are in blue. Viewed with confocal microscopy

Biogen pulls application for Alzheimer's drug in Europe

The drugmaker said the move follows interactions with the European Medicines Agency that suggested data provided so far would not be enough to support an approval.

A sign marks a Biogen facility, some of whose employees have tested positive for the coronavirus after attending a meeting in Boston, in Cambridge, Massachusetts, US, March 9, 2020.

Japan's Kowa says Ivermectin showed 'antiviral effect' against Omicron

Clinical trials are ongoing, but promotion of ivermectin as a COVID-19 treatment has generated controversy.

Ivermectin

Biogen shares slide as Medicare restricts cover of Alzheimer's treatments

The coverage decision by US Centers for Medicare and Medicaid Services (CMS), the health agency that runs Medicare, crushes any hopes of the drug Aduhelm gaining traction.

Aduhelm, Biogen's controversial recently approved drug for early Alzheimer's disease, is seen at Butler Hospital, one of the clinical research sites in Providence, Rhode Island, US, June 16, 2021.